OncoMatch/Clinical Trials/NCT03772028

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Is NCT03772028 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies cisplatin for ovarian cancer.

Phase 3RecruitingThe Netherlands Cancer InstituteNCT03772028Data as of May 2026

Treatment: cisplatin — stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage FIGO STAGE III (FIGO)

Excluded: Stage FIGO STAGE IV

histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer; FIGO stage IV disease [excluded]

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any prior treatment for the current malignancy

prior treatment for the current malignancy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

City of Hope · Duarte, California
MSKCC New York · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify